Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed Or Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableStudy completedNCT00049465
What this trial is testing

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

Who this might be right for
Cancer
Fred Hutchinson Cancer Center
Testing effectiveness (Phase 2)Study completedNCT00089011
What this trial is testing

Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in Remission+171 more
Fred Hutchinson Cancer Center 150
Large-scale testing (Phase 3)Study completedNCT02136134
What this trial is testing

Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 498
Early research (Phase 1)Active Not RecruitingNCT05981209
What this trial is testing

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

Who this might be right for
Recurrent Multiple MyelomaRefractory Multiple Myeloma
Abdullah Khan 12
Early research (Phase 1)Ended earlyNCT04405167
What this trial is testing

Tasquinimod for the Treatment of Relapsed or Refractory Myeloma

Who this might be right for
Multiple Myeloma
University of Pennsylvania 30
Testing effectiveness (Phase 2)WithdrawnNCT05647512
What this trial is testing

Study of LM-305 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) and Other Plasma Cell Diseases

Who this might be right for
Relapsed or Refractory Multiple MyelomaOther Plasma Cell Diseases
LaNova Medicines Limited
Testing effectiveness (Phase 2)Ended earlyNCT00648739
What this trial is testing

Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MM

Who this might be right for
B-cell Chronic Lymphocytic LeukemiaMultiple Myeloma
Alexion Pharmaceuticals, Inc. 26
Early research (Phase 1)Study completedNCT00710528
What this trial is testing

Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Chronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)Acute Myeloid Leukemia (AML)+1 more
Gilead Sciences 192
Not applicableUnknownNCT05822037
What this trial is testing

CT0594CP CAR-T Cells in Patients With Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
The First Affiliated Hospital of Soochow University 6
Very early researchUnknownNCT05486975
What this trial is testing

This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
The First Affiliated Hospital of Soochow University 18
Testing effectiveness (Phase 2)Study completedNCT03312530
What this trial is testing

Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Hoffmann-La Roche 49
Testing effectiveness (Phase 2)UnknownNCT05749133
What this trial is testing

Safety and Efficacy of Anti-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, Refractory
XuYan 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT04557098
What this trial is testing

Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Hematological Malignancies
Janssen Research & Development, LLC 194
Early research (Phase 1)Study completedNCT03650491
What this trial is testing

FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma With Failed Remission
Fortis Therapeutics, Inc. 31
Testing effectiveness (Phase 2)Study completedNCT00216697
What this trial is testing

An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

Who this might be right for
Multiple Myeloma
Janssen Pharmaceutical K.K. 13
Testing effectiveness (Phase 2)Study completedNCT01351623
What this trial is testing

Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Memorial Sloan Kettering Cancer Center 44
Testing effectiveness (Phase 2)Study completedNCT02612779
What this trial is testing

Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

Who this might be right for
Multiple Myeloma
Bristol-Myers Squibb 74
Testing effectiveness (Phase 2)Looking for participantsNCT06182696
What this trial is testing

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
OriCell Therapeutics Co., Ltd. 83
Testing effectiveness (Phase 2)Study completedNCT02467010
What this trial is testing

Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance

Who this might be right for
Multiple Myeloma
University Medical Center Groningen 73
Large-scale testing (Phase 3)Looking for participantsNCT06615479
What this trial is testing

Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Who this might be right for
Relapsed or Refractory Multiple Myeloma (RRMM)
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 440
Next Page